Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

248.95 USD +2.07 (+0.84%)
Official Closing Price Updated: 7:56 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Amgen to Acquire Rodeo Therapeutics Corporation
Preclinical Program Targeting 15-PGDH has Potential use in a Broad Range of Therapeutic Applications Including Inflammatory Disease Indications 
From PR Newswire
NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) Developing Groundbreaking Anti-Inflammatory Therapeutics
From InvestorBrandNetwork
Controlling Inflammation to Stop Disease
From InvestorBrandNetwork
Controlling Inflammation to Stop Disease
NetworkNewsWire Editorial Coverage 
From PR Newswire
Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference
Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, March 16, 2021. David M. Reese, M.D., executive vice president of Research and... 
From PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Five Prime Therapeutics, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc. ("Five Prime" or the "Company") (NASDAQ: FPRX)... 
From PR Newswire
FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
AMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH 
From Business Wire News Releases
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide 
From PR Newswire
Amgen Announces 2021 Second Quarter Dividend
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021, to all stockholders of... 
From PR Newswire
BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Phase 3 Results Published in The Journal of The American Medical Association 
From PR Newswire
Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Data From Investigational Therapy Tezepelumab Phase 3 NAVIGATOR Trial in Patients With Severe Asthma Presented at the American Academy of Asthma Allergy & Immunology Annual Meeting 
From PR Newswire
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
Moderna reports fourth quarter and fiscal year 2020 financial results and provides business updates. 
From Business Wire News Releases
Amgen To Present At The Cowen 41st Annual Healthcare Conference
Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon, executive vice president of Global Commercial... 
From PR Newswire
Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting on Friday, Feb. 26, at... 
From PR Newswire
Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis
Filing Based on Data From Phase 3 ADVANCE Study 
From PR Newswire
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
FDA Target Action Date is Aug. 16, 2021 
From PR Newswire
Amgen To Present At Guggenheim Healthcare Talks Oncology Day
Amgen (NASDAQ:AMGN) today announced that Greg Friberg, vice president and global oncology therapeutic area head at Amgen, will participate in a fireside chat as part of the Guggenheim Healthcare Talks... 
From PR Newswire
Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups
Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits 
From PR Newswire
Amgen Reports Fourth Quarter And Full Year 2020 Financial Results
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include: 
From PR Newswire
Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China
Sotorasib is for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS G12C Mutation 
From PR Newswire
Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results
Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, Feb. 2, 2021, after the close of the U.S. financial markets. The announcement... 
From PR Newswire
Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
37.1% of Patients Responded to Sotorasib Treatment, With a Median Duration of Response of 10 Months 
From PR Newswire
Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2020 World Conference on Lung Cancer (WCLC) on Friday, Jan. 29, at 8:00 p.m. ET. David M. Reese, M.D.,... 
From PR Newswire
Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020
Registrational Phase 2 Non-Small Cell Lung Cancer Results for Investigational KRAS G12C Inhibitor Sotorasib to be Featured in the Presidential Symposium 
From PR Newswire
José M. Vega, M.D. Joins Moderna as Chief Safety Officer
José M. Vega, M.D. joins Moderna as Chief Safety Officer. 
From Business Wire News Releases
Amgen To Achieve Carbon Neutrality By 2027
Amgen (NASDAQ: AMGN) today announced the launch of a new seven-year environmental sustainability plan, which includes a commitment to achieve carbon neutrality, while also reducing water use by 40% and... 
From PR Newswire
GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN),... 
From Business Wire News Releases
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines 
From Business Wire News Releases
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
Corinne Le Goff, Pharm.D. will join Moderna as Chief Commercial Officer on January 19. 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.